23andMe Secures $39 Million in Funding to Accelerate Genetic Research and Drug Discovery Programs

23andMe, the pioneering consumer genetics and research company based in Sunnyvale, CA, has successfully raised $3.9 million in its latest funding round to further its mission of empowering people through genetic insights. Founded in 2006, 23andMe has established itself as a leader in the field, offering consumers unprecedented access to their genetic information, including multiple FDA-authorized reports on genetic health risks. The company's innovative crowdsourced research platform boasts over 80 percent customer participation, contributing to groundbreaking studies that have resulted in more than 180 scientific publications elucidating the genetic bases of various diseases, conditions, and personal traits. With this new capital, 23andMe plans to enhance its research capabilities and accelerate the development of its Therapeutics group, which is focused on drug discovery initiatives targeting critical health issues such as oncology, respiratory conditions, and cardiovascular diseases. This funding not only reaffirms investor confidence in the company's vision but also positions 23andMe to make significant strides in translating genetic research into tangible therapeutic solutions. Recognized as one of the San Francisco Chronicle's Top Workplaces and lauded for its inclusive corporate culture, 23andMe continues to be a driving force in the genetics industry under the leadership of CEO Anne Wojcicki, who has garnered accolades for her commitment to workplace excellence and diversity. With eyes set on expanding its research and therapeutic reach, 23andMe remains dedicated to helping individuals harness the power of their genomes for better health outcomes. For further details, visit www.23andMe.com.